CIK 0001677077
- Emerging growth company
Alzamend Neuro, Inc.
Sign in to watch- Ticker
- ALZN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Apr 30
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 811822909
- Phone
- +1 844-722-6333
- Business address
- 480 PEACHTREE ROAD NE, SECOND FLOOR, SUITE 103, ATLANTA, GA, 30326
- 4 Open-market sale Director sold 139,412 shares at an average $2.47 ($344,222)
- 4 Open-market sale Director sold 123,366 shares at an average $2.41 ($296,789)
- 4 Open-market sale Director sold 79,628 shares at an average $2.31 ($184,156)
- 4 Open-market sale Director sold 97,006 shares at an average $2.34 ($226,923)
- 4 Open-market sale Director sold 77,009 shares at $2.35 ($180,856)
- 4 Open-market sale Director sold 22,991 shares at an average $2.47 ($56,696)
- 4 Open-market sale Director sold 129,449 shares at an average $2.28 ($295,532)
- 4 Open-market sale Director sold 44,843 shares at an average $2.86 ($128,169)
- 4 Open-market sale Director sold 69,137 shares at an average $2.95 ($203,821)
- 4 Open-market sale Director sold 1,224 shares at an average $5.06 ($6,196)
- 4 Open-market buy Director bought 3,334 shares at $0.99 ($3,285)
- 4 Open-market buy Director bought 2,905 shares at $1.02 ($2,969)
- 4 Open-market buy Chief Financial Officer bought 5,000 shares at $1.01 ($5,048)
- 4 Open-market buy Director bought 5,000 shares at $0.98 ($4,892)
- 4 Open-market buy Director bought 5,000 shares at $0.97 ($4,852)
- 4 Open-market buy Director bought 5,000 shares at $0.96 ($4,810)
- 4 Open-market buy Director bought 100 shares at $0.68 ($68)
- 4 Open-market buy Director bought 75 shares at $2.75 ($206)
- 4 Open-market buy Director bought 25 shares at $3.74 ($93)
- 5 Insider Annual Insider Trading Report
Page 2 of 9 · 170 filings